查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2032329

眼科藥品市場報告：按類型、藥物類別、適應症、劑型、分銷管道和地區分類（2026-2034 年）

Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3個工作天內

價格

2025年全球眼科藥品市場規模達493億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到726億美元，2026年至2034年的複合年成長率為4.26%。推動該市場成長的因素包括：眼科疾病患者數量不斷增加、藥物輸送系統技術的顯著進步、政府有利的政策和資金支持、人口老齡化以及糖尿病患者數量的成長。

眼科藥品市場趨勢：

眼科疾病發生率上升

全球眼科疾病的增加顯著推動了眼科藥物的需求成長。數據顯示，白內障、青光眼、老齡化黃斑部病變（AMD）和糖尿病視網膜病變等疾病是推動市場成長的主要因素。世界衛生組織（WHO）的數據顯示，每年至少有22億人有近視或遠視。報告也指出，其中至少有10億例視力障礙病例原本可以避免或預防。眼科疾病患者的增加導致對青光眼藥物、抗血管內皮生長因子（VEGF）藥物和抗發炎藥物等治療藥物的需求顯著上升。眾多市場研究報告也印證了這一關聯，這些報告重點介紹了前景廣闊的先進治療方案，並推動了眼科藥物市場的最新發展趨勢。

藥物輸送系統的重大技術進步

新科技在藥物遞送系統的創新是改善眼科藥物市場格局的重要因素。微乳劑、奈米技術和眼內植入物等新型製劑的潛力在於提高藥物的療效、安全性和患者依從性。例如，奈米級藥物載體可以顯著提高藥物在眼部組織的生物利用度，從而減少給藥頻率和藥物相關副作用。因此，越來越多的公司正在投資這些技術以獲得市場競爭優勢。目前，與新型眼科藥物遞送系統相關的專利數量正在不斷增加。上述所有研發投資都基於市場成長預測，這些預測表明，受益於新型藥物遞送技術的細分市場有望實現成長。這表明，這些技術有可能顯著改變目前的眼科治療模式。

政府的利多措施和資金

政府政策在改善眼科藥品市場前景方面發揮著至關重要的作用。世界各國政府正在啟動各種措施來改善醫療基礎設施，包括提高獲得有效眼科醫療服務的可近性。例如，許多國家提供各種機會，例如為眼科醫療中心的建立和發展提供津貼、投資新藥研發以及普及眼科疾病知識。在美國，國家眼科研究所為眼科領域的研究提供了大量資金。這促進了該領域的重大突破，為改善視力開闢了新藥和行業機會。此外，透過FDA的「突破性療法」認定等途徑快速核准藥物，也促進了突破性眼科解決方案進入市場。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 次要訊息
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球眼科藥品市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依類型

  • 處方藥
  • 非處方藥

第7章 市場區隔：依藥物類別分類

  • 青光眼治療藥物
  • 感染疾病物
  • 抗發炎藥
  • 抗過敏
  • 其他

第8章 市場區隔：依適應症分類

  • 乾眼症
  • 青光眼
  • 感染疾病、發炎和過敏
  • 視網膜疾病
  • 其他

第9章 市場區隔：依劑型分類

  • 液體眼科製劑
  • 固態眼科製劑
  • 半固態眼用製劑
  • 多房間給藥系統
  • 其他

第10章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 藥局
  • 網路藥房
  • 其他

第11章 市場區隔：按地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第12章 SWOT 分析

第13章：價值鏈分析

第14章：波特五力分析

第15章：價格分析

第16章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • AbbVie Inc.
    • Aerie Pharmaceuticals Inc.
    • Akorn Inc.
    • Alcon
    • Bausch Health Companies Inc.
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Santen Pharmaceutical Co. Ltd.
    • Sun Pharmaceutical Industries Ltd.
Product Code: SR112026A5287

The global ophthalmic drugs market size reached USD 49.3 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 72.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.26% during 2026-2034. The market is propelled by the rising number of individuals diagnosed with eye diseases, significant technological advancements in drug delivery systems, favorable government initiatives and funding, rising geriatric population, and increasing number of individuals suffering with diabetes.

Ophthalmic Drugs Market Analysis:

Major Market Drivers: The rising issues related to eyes, significant developments in drug formulations, and robust investment in technology and pharmaceutical research sectors are some of the major market drivers driving the ophthalmic drugs growth.

Key Market Trends: The rising number of individuals opting for combination therapies, increasing strategic partnerships among industry players, and the rising emphasis on creating treatments for conditions that were considered untreatable previously are some of the ophthalmic drugs market trends.

Geographical Trends: North America leads the market on account of a strong healthcare infrastructure and the increasing amount of diagnosis of diabetes-related eye conditions. The second largest market of the industry is Europe due to its rising aging population and increasing research and development (R&D) activities across the region.

Competitive Landscape: AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd, are among some of the key players in the ophthalmic drugs industry.

Challenges and Opportunities: Challenges of this market include the strict regulatory environments which lead to a delay in drug approvals and rising cost of developed ophthalmic drugs. Moreover, ophthalmic drugs market recent opportunities include the potential of the emerging markets accredited to the rising healthcare access.

Ophthalmic Drugs Market Trends:

Rising Prevalence of Eye Diseases Among Individuals

The increasing eye-related issues worldwide are majorly escalating the ophthalmic drugs demand. As per the data, illnesses such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are driving the market. According to the WORLD HEALTH ORGANIZATION (WHO), at least 2.2 Billion individuals each year have a near of distance vision impairment. The report also states that minimum 1 Billion of these cases of vision impairment could have been avoided or is yet to be prevented. The rising number of individuals with eye diseases are significantly leading to a rise in the demand for these therapeutic drugs such as anti-glaucoma medications, anti-VEGF agents, and anti-inflammatory agents. This correlation is supported by numerous market research reports which depict promising advanced treatment solutions and promote ophthalmic drugs market recent development activities.

Significant Technological Advancements in Drug Delivery Systems

The innovation of drug delivery systems, which can be accredited to novel technologies has been a major factor in creating a positive ophthalmic drugs market overview. New formulation possibilities such as microemulsions, nanotechnology, or ocular inserts offer better efficacy, safety, and patient adherence. For instance, drug carriers at a nano-size scale can significantly improve the bioavailability of the drug to the targeted ocular tissues, thereby reducing the need for frequent dosing and any side effects associated with the drug. As a result, more companies are investing in these technologies in order to gain a competitive edge in the market. There is a growing number of novel ophthalmic drug delivery system patents in the industry. All of the aforementioned research and development (R&D) investments are underpinned by the projections of market growth within the segments that benefit from new drug delivery technologies. This implies their ability to significantly disrupt the present ophthalmology treatment paradigm.

Favorable Government Initiatives and Funding

Government policies and act as a vital factor creating a positive ophthalmic drugs market outlook. Governments worldwide have launched various initiatives to improve healthcare infrastructure, including making effective eye care more accessible. For instance, numerous countries provide opportunities for subsidizing the opening and development of eye care centers, investing in research to create new drugs, and spreading information about eye diseases. In the United States, the National Eye Institute provides significant funding for research in the ophthalmic field. This propels a significant breakthrough in this area, opening up new drugs and opportunities in the industry for good vision. Moreover, faster drug approvals through routes such as FDA's Breakthrough Therapy designation improve market entry for visionary ophthalmic solutions.

Ophthalmic Drugs Industry Segmentation:

This report provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. The report categorizes the market based on type, drug class, indication, dosage form, and distribution channel.

Breakup by Type:

  • Prescription Drugs
  • Over-the-counter Drugs

Prescription drugs accounts for the majority of the market share

The highest ophthalmic drugs market revenue is deriving from prescription drugs. This can be accredited to the requirement of regulated forms of treatment for certain complex or severe eye disorders. Glaucoma, age-regulated macular degeneration, diabetic retinopathy, and many other conditions are typically treated with prescription medication that must be administered in precise dosages and only used through patient monitoring by a healthcare provider. Age-related macular degeneration can be categorized as dry AMD and wet AMD, and is a primary case of vision loss in individuals 50 years or older. Approximately 80% of individuals (8 out of 10) are diagnosed with dry form AMD. The rapid growth of the patient population proves the irreplaceability of prescription drugs in successful disease treatment and therapy.

Breakup by Drug Class:

  • Anti-glaucoma
  • Anti-infection
  • Anti-inflammation
  • Anti-allergy
  • Others

Anti-glaucoma holds the largest share in the industry

The largest ophthalmic drugs market share is held by anti-glaucoma drugs, where glaucoma is the second leading cause of irreversible blindness globally. According to the NATIONAL INSTITUE OF HEALTH (NIH), the number of individuals suffering with glaucoma globally will rise upto 111.8 million by 2040. A rapidly growing glaucoma patient population signifies that patients need effective therapeutics on a long-term basis in order to maintain visual function, and hence there is significant demand for this segment. Additionally, drug formulation is constantly being developed to achieve maximum relief for glaucoma patients and compliance with the treatment on the part of the patient.

Breakup by Indication:

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
  • Others

Retinal disorders represent the leading market segment

Retinal disorders account for a large part of the ophthalmic drugs market, mainly due to the high frequency of diseases and their severity, which includes diabetic retinopathy and age-related macular degeneration. As per a report published by the NATIONAL INSTITUE OF HEALTH (NIH), individuals diagnosed with type 1, type 2, and gestational diabetes are more prone to diabetic retinopathy. The report also suggested that diabetic retinopathy can also lead to other serious eye conditions, such as diabetic macular edema and neovascular glaucoma. With time, approximately 1 in 15 individuals with diabetes develop DME. In the absence of treatment, these diseases often lead to complete blindness and require constant drug support, due to which the consumption of drugs in this segment is significant.

Breakup by Dosage Form:

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Others

Liquid ophthalmic drug forms exhibit a clear dominance in the market

On account of the need for easily administered and fast-acting medication directly into the eye, liquid ophthalmic drugs are the largest segment in the market by dosage form. Liquid dosage forms include drops, solutions, tinctures, injections, tinctures, elixirs, and syrups. Considering the relatively wide range of methods for delivering liquid medication into the eye, drops are the most prevalent, offering better controllability of dosage and higher patient adherence, thus impelling the ophthalmic drugs market growth. As per the NATIONAL INSTITUTE OF HEALTH (NIH), demand for liquid ophthalmic formulations is prominently high, with 90% of prescribed medications being eye drops. It is also driven by the introduction of non-preserved and multi-dose packaging, which increases convenience and safety. Thus, liquid formulations are widely preferred by patient and healthcare providers in cases of eye conditions.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

Hospital pharmacies dominates the market

In the market breakup by distribution channel, hospital pharmacies currently constitute the largest segment. The factor dictating this is the direct integration of these pharmacies into the healthcare facilities and immediate patient care. As a result, patients have timely access to the ophthalmic medications prescribed by their ophthalmologists. Early treatment of acute and chronic eye conditions is essential to prevent vision impairment and blindness. Hospital pharmacies, in turn, are the first to receive new drug approvals, given their affiliation with manufacturers and the purchasing power. As a result, the drug distribution and administration process are facilitated, patient adherence improves, and outcomes enhance.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest ophthalmic drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America holds the largest market share due to the developed healthcare system of the region, high healthcare expenditures, and strong presence of big pharma. Moreover, the eye disease rate in the North is high due to glaucoma, for instance, according to the NATIONAL HEALTH INSTITUE (NIH), 3 million individuals in the United States are affected by glaucoma. Another prominent reason is the sponsorship of the United States in medical research, with eye treatment gaining notable financial support.

Competitive Landscape:

The ophthalmic drugs market report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the metal fiber industry include AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

1. How big is the ophthalmic drugs market?

2. What is the future outlook of ophthalmic drugs market?

3. What are the key factors driving the ophthalmic drugs market?

4. Which region accounts for the largest ophthalmic drugs market share?

5. Which are the leading companies in the global ophthalmic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ophthalmic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Prescription Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Over-the-counter Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Anti-glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Anti-infection
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Anti-inflammation
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Anti-allergy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Dry Eye
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Glaucoma
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infection/Inflammation/Allergy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Retinal Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Dosage Form

  • 9.1 Liquid Ophthalmic Drug Forms
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Solid Ophthalmic Drug Forms
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Semisolid Ophthalmic Drug Forms
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Multicompartment Drug Delivery Systems
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Drug Stores
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Aerie Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Akorn Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Alcon
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Bausch Health Companies Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Bayer AG
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 F. Hoffmann-La Roche AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Regeneron Pharmaceuticals Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Santen Pharmaceutical Co. Ltd.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
    • 16.3.13 Sun Pharmaceutical Industries Ltd.
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio

List of Figures

  • Figure 1: Global: Ophthalmic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Ophthalmic Drugs Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Ophthalmic Drugs Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 4: Global: Ophthalmic Drugs Market: Breakup by Type (in %), 2025
  • Figure 5: Global: Ophthalmic Drugs Market: Breakup by Drug Class (in %), 2025
  • Figure 6: Global: Ophthalmic Drugs Market: Breakup by Indication (in %), 2025
  • Figure 7: Global: Ophthalmic Drugs Market: Breakup by Dosage Form (in %), 2025
  • Figure 8: Global: Ophthalmic Drugs Market: Breakup by Distribution Channel (in %), 2025
  • Figure 9: Global: Ophthalmic Drugs Market: Breakup by Region (in %), 2025
  • Figure 10: Global: Ophthalmic Drugs (Prescription Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Ophthalmic Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Ophthalmic Drugs (Anti-glaucoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Ophthalmic Drugs (Anti-glaucoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Ophthalmic Drugs (Anti-infection) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Ophthalmic Drugs (Anti-infection) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Ophthalmic Drugs (Anti-inflammation) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Ophthalmic Drugs (Anti-inflammation) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Ophthalmic Drugs (Anti-allergy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Ophthalmic Drugs (Anti-allergy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Ophthalmic Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Ophthalmic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Ophthalmic Drugs (Dry Eye) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Ophthalmic Drugs (Dry Eye) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Ophthalmic Drugs (Glaucoma) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Ophthalmic Drugs (Glaucoma) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Ophthalmic Drugs (Retinal Disorders) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Ophthalmic Drugs (Retinal Disorders) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Ophthalmic Drugs (Other Indications) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Ophthalmic Drugs (Other Indications) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Global: Ophthalmic Drugs (Other Dosage Forms) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Global: Ophthalmic Drugs (Other Dosage Forms) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Global: Ophthalmic Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Global: Ophthalmic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Global: Ophthalmic Drugs (Drug Stores) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Global: Ophthalmic Drugs (Drug Stores) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Global: Ophthalmic Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Global: Ophthalmic Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Global: Ophthalmic Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Global: Ophthalmic Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: North America: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: North America: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: United States: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: United States: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: Canada: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: Canada: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Asia-Pacific: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Asia-Pacific: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: China: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: China: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Japan: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Japan: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: India: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: India: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: South Korea: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: South Korea: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Australia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Australia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Indonesia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Indonesia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Europe: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Europe: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Germany: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Germany: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: France: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: France: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: United Kingdom: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: United Kingdom: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Italy: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Italy: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Spain: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Spain: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Russia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Russia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Latin America: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 91: Latin America: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Brazil: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 93: Brazil: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 94: Mexico: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 95: Mexico: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 96: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 97: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 98: Middle East and Africa: Ophthalmic Drugs Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 99: Middle East and Africa: Ophthalmic Drugs Market: Breakup by Country (in %), 2025
  • Figure 100: Middle East and Africa: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 101: Global: Ophthalmic Drugs Industry: SWOT Analysis
  • Figure 102: Global: Ophthalmic Drugs Industry: Value Chain Analysis
  • Figure 103: Global: Ophthalmic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ophthalmic Drugs Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Ophthalmic Drugs Market Forecast: Breakup by Type (in Million USD), 2026-2034
  • Table 3: Global: Ophthalmic Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2026-2034
  • Table 4: Global: Ophthalmic Drugs Market Forecast: Breakup by Indication (in Million USD), 2026-2034
  • Table 5: Global: Ophthalmic Drugs Market Forecast: Breakup by Dosage Form (in Million USD), 2026-2034
  • Table 6: Global: Ophthalmic Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 7: Global: Ophthalmic Drugs Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 8: Global: Ophthalmic Drugs Market: Competitive Structure
  • Table 9: Global: Ophthalmic Drugs Market: Key Players